Histamine H3 receptor blockade improves cardiac function in canine anaphylaxis.
In anaphylactic shock (AS), the relative effects of the autacoids including histamine, prostaglandins, and leukotrienes on causing cardiovascular collapse and the extent to which receptor blocking agents and pathway inhibitors may prevent this collapse are not clear. In a ragweed model of anaphylaxis, we examined whether pretreatment with H1, H2, H3 receptor blockers, and cyclooxygenase and leukotriene pathway inhibitors was useful in preventing the depression in left ventricular (LV) contractility known to occur in this model. The dose of allergen was varied to produce similar degrees of shock between treatments. The animals were studied under pentobarbital anesthesia in which the treatment studies were approximately 3 wk apart. LV volumes were measured by sonomicrometric techniques. During challenge, mean arterial blood pressure (Pa), cardiac output (Q), and LV end-diastolic pressure (LVEDP) decreased approximately 50% compared with preshock values in all treatments. Histamine H3 receptor blockade was associated with higher heart rates (HR) and higher stroke work (SW) (p < 0.05) as compared with the other treatment studies. We conclude that histamine H3 activation by inhibiting adrenergic neural norepinephrine release contributes to cardiovascular collapse in AS.
Chrusch
C
C
Department of Medicine, Section of Respiratory Disease, Winnipeg, Manitoba, Canada.
Sharma
S
S
Unruh
H
H
Bautista
E
E
Duke
K
K
Becker
A
A
Kepron
W
W
Mink
S N
SN
D000707:Anaphylaxis / Q000188:drug therapy / Q000503:physiopathology*; D000818:Animals; D002744:Chlorpheniramine / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects; D006632:Histamine / Q000502:physiology; D006633:Histamine Antagonists / Q000494:pharmacology*; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D015289:Leukotrienes / Q000502:physiology; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D009200:Myocardial Contraction / Q000187:drug effects; D010880:Piperidines / Q000494:pharmacology; D011453:Prostaglandins / Q000502:physiology; D011804:Quinolines / Q000494:pharmacology; D011899:Ranitidine / Q000494:pharmacology; D018100:Receptors, Histamine H3 / Q000502:physiology*; D013318:Stroke Volume / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects*
D016861:Cyclooxygenase Inhibitors; D006633:Histamine Antagonists; D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D007211:Indoles; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D010880:Piperidines; D011453:Prostaglandins; D011804:Quinolines; D018100:Receptors, Histamine H3; C078266:MK 0591; D002744:Chlorpheniramine; D006632:Histamine; D011899:Ranitidine; C052075:thioperamide; D007213:Indomethacin